BioVaxys Technology Corp. (BVAXF)
USD 0.02
(1.6%)
USD 0.02
(1.6%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.4 Million CAD | -41.14% |
| 2022 | 4.08 Million CAD | -36.64% |
| 2021 | 6.44 Million CAD | 486.5% |
| 2020 | 1.09 Million CAD | 377.75% |
| 2019 | 229.9 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 370.7 Thousand CAD | -91.16% |
| 2024 Q2 | 539.18 Thousand CAD | 45.45% |
| 2024 Q3 | 802.18 Thousand CAD | 48.78% |
| 2023 Q2 | 782.8 Thousand CAD | -14.45% |
| 2023 Q1 | 915.06 Thousand CAD | -0.96% |
| 2023 FY | 6.45 Million CAD | 58.1% |
| 2023 Q4 | 4.19 Million CAD | 645.8% |
| 2023 Q3 | 562.22 Thousand CAD | -28.18% |
| 2022 Q4 | 923.95 Thousand CAD | 1.6% |
| 2022 Q3 | 909.43 Thousand CAD | -12.55% |
| 2022 FY | 4.08 Million CAD | -36.64% |
| 2022 Q2 | 1.04 Million CAD | -13.93% |
| 2022 Q1 | 1.2 Million CAD | -51.95% |
| 2021 Q4 | 2.51 Million CAD | 181.52% |
| 2021 FY | 6.44 Million CAD | 486.5% |
| 2021 Q3 | 893.39 Thousand CAD | -40.27% |
| 2021 Q2 | 1.49 Million CAD | -2.75% |
| 2021 Q1 | 1.53 Million CAD | 91.76% |
| 2020 Q3 | 197.33 Thousand CAD | 201.65% |
| 2020 Q1 | 33.6 Thousand CAD | -50.49% |
| 2020 FY | 1.09 Million CAD | 377.75% |
| 2020 Q4 | 802.03 Thousand CAD | 306.44% |
| 2020 Q2 | 65.41 Thousand CAD | 94.64% |
| 2019 Q3 | 37.81 Thousand CAD | -35.65% |
| 2019 Q1 | 65.44 Thousand CAD | -49.77% |
| 2019 FY | 229.9 Thousand CAD | 0.0% |
| 2019 Q4 | 67.88 Thousand CAD | 79.53% |
| 2019 Q2 | 58.76 Thousand CAD | -10.21% |
| 2018 Q4 | 130.28 Thousand CAD | 321.14% |
| 2018 Q3 | 30.93 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Agentix Corp. | 1.37 Million USD | -75.148% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 52.349% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 34.188% |
| Biomind Labs Inc. | 994.18 Thousand USD | -141.666% |
| ContraFect Corporation | 56.88 Million USD | 95.777% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -79.092% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 8.56% |
| CSL Limited | 3.44 Billion USD | 99.93% |
| CytoDyn Inc. | 18.05 Million USD | 86.695% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 91.87% |
| GB Sciences, Inc. | 1.42 Million USD | -69.137% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -28.869% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 29.439% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -516.738% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -991.705% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 95.817% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -478.273% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -59.971% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -160.16% |
| Skye Bioscience, Inc. | 13.54 Million USD | 82.265% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 93.551% |
| SQZ Biotechnologies Company | 85.61 Million USD | 97.194% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -17.274% |
| Zenith Capital Corp. | 8.94 Million USD | 73.134% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 97.232% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 17.613% |
| Mesoblast Limited | 5.9 Million USD | 59.292% |
| Marizyme, Inc. | 19.23 Million USD | 87.512% |
| Genus plc | 147.7 Million USD | 98.373% |
| Pharming Group N.V. | 225.49 Million USD | 98.935% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 71.188% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -62.475% |
| IMV Inc. | 37.7 Million USD | 93.629% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 13.896% |
| MultiCell Technologies, Inc. | 567.42 USD | -423325.681% |
| ONE Bio Corp. | 6.44 Million USD | 62.715% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 97.204% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 90.279% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -36.536% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 64.236% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 9710.408% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 84.993% |
| Alpha Cognition Inc. | 9.7 Million USD | 75.245% |
| Enzolytics Inc. | 2.17 Million USD | -10.236% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.843% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -130.134% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 0.097% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.709% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 51.146% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -817.984% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 2.147% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1300.861% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -25.077% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 72.633% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 45.503% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 3.74 Million USD | 35.869% |
| Helix BioMedix, Inc. | 1.97 Million USD | -21.834% |
| EV Biologics, Inc. | 531.96 Thousand USD | -351.649% |
| Q BioMed Inc. | 3.43 Million USD | 30.088% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 77.891% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 97.581% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | 89.542% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -30.925% |
| HST Global, Inc. | 140.9 Thousand USD | -1605.098% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -79.912% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -113.582% |
| Halberd Corporation | 74.84 Thousand USD | -3110.232% |
| Resverlogix Corp. | 12.71 Million USD | 81.1% |
| Cell Source, Inc. | 4.32 Million USD | 44.453% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -52.126% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.31 Million USD | 67.134% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -13691.413% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | 2.601% |
| Kadimastem Ltd | 2.41 Million USD | 0.312% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 43.314% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1223.857% |
| LadRx Corporation | 3.81 Million USD | 36.969% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -160.16% |
| Affymax, Inc. | 39.38 Million USD | 93.9% |
| Itoco Inc. | 919.14 Thousand USD | -161.396% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -114.71% |
| Mobile Lads Corp. | 554.54 Thousand USD | -333.256% |
| International Stem Cell Corporation | 5.27 Million USD | 54.418% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 3.82 Million USD | 37.107% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -9445.878% |
| Qrons Inc. | 643.67 Thousand USD | -273.262% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -69.222% |
| SYBLEU INC | 160.87 Thousand USD | -1393.45% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -7.746% |
| Rebus Holdings, Inc. | 664 Thousand USD | -261.838% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -32.279% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -4464.04% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -11710.461% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 93.375% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -48.492% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -226.514% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 22.771% |
| Neutra Corp. | 243.82 Thousand USD | -885.396% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 86.237% |
| PureTech Health plc | 144.59 Million USD | 98.338% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 88.274% |
| IXICO plc | 4.7 Million USD | 48.957% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 72.688% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 97.96% |
| CSL Limited | 3.89 Billion USD | 99.938% |
| Cellectis S.A. | 97.32 Million USD | 97.531% |